Sarcoma, Alveolar Soft Part - 20 Studies Found
Completed |
: Phase 2 Study in Patients With MiT Tumors :
|
Active, not recruiting |
: Trial of Dasatinib in Advanced Sarcomas :
|
Not yet recruiting |
: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors :
: 2016-08-15 : |
Not yet recruiting |
: Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma :
: |
Recruiting |
: CREATE: Cross-tumoral Phase 2 With Crizotinib :
|
Recruiting |
: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery :
|
Recruiting |
: Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma :
: |
Completed |
: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma :
: |
Completed |
: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma :
: Drug: romidepsin DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpa |
Active, not recruiting |
: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma :
: |